Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept versus Ranibizumab for Retinopathy of Prematurity.

Enzhong Jin,Juan Chen,Yufei Gui,Hong Yin,Jian Zhang,Mingwei Zhao,Jianhong Liang,Xiao-xin Li

doi:10.1155/2019/3935945

Enzhong Jin, Juan Chen + Show 6 more

Open Access

https://doi.org/10.1155/2019/3935945

Copy DOI

Abstract

Purpose To evaluate angiographic findings of peripheral retina vasculature in retinopathy of prematurity (ROP) neonates who received intravitreal conbercept (IVC) or ranibizumab (IVR). Methods Fluorescein angiography (FA) findings were retrospectively evaluated for ROP neonates who received IVC or IVR. Outcome measures included peripheral avascular zone, vascular leakage, vascular blunting, vascular loops, vascular dilatation, arteriovenous shunt, and capillary dropout. Results Fifty-four eyes (28 patients) with ROP were included. Twenty-nine eyes (15 patients) received IVC, and 25 eyes (13 patients) received IVR. For infants of the IVC group, the mean gestational age, birth weight, and postmenstrual age (PMA) at the initial treatment were 28.96 ± 2.36 weeks, 1168.8 ± 344.5 g, and 41.22 ± 4.39 weeks, respectively. For the IVR group, they were 28.83 ± 2.34 weeks, 1255.0 ± 356.9 g, and 39.42 ± 2.77 weeks, respectively (P=0.817, 0.522, and 0.075). For the IVC group, FA performed at 71.29–115.43 weeks PMA showed 96.55% of eyes had avascular zone; vascular leakage was found in 24.14% eyes; vascular blunting, vascular dilation, vascular loops, arteriovenous shunt, and capillary dropout were found in 96.55%, 72.41%, 79.31%, 48.28%, and 68.97% eyes, respectively. For the IVR group, FA performed at 65.57–133.71 weeks PMA showed 92.0% of eyes had avascular zone; vascular leakage was found in 40.0% eyes; vascular blunting, dilatation, loops, arteriovenous shunt, and capillary dropout were found in 100%, 60.0%, 64.0%, 36.0%, and 68.0% eyes, respectively. Conclusion No significant difference can be observed between the IVC group and IVR group for peripheral vascular structure anomalies with FA evidence. FA studies should be considered to assess the status of the peripheral retinal vasculature to determine therapeutic outcomes and potential functional outcomes.

Highlights

Retinopathy of prematurity (ROP) is a vascular disorder of immature retina developed in premature infants
The side effect of this treatment including visual field loss caused by permanent ablation of the hypoxic retina and subsequent high myopia should not be ignored [7, 8]. e off-label intravitreal injection of anti-Vascular endothelial growth factor (VEGF) agents such as conbercept (KH902; Chengdu Kanghong Biotech Co, Ltd, Sichuan, China), bevacizumab (Genentech, Inc, South San Francisco, CA), ranibizumab (Genentech, Inc and Novartis International AG, Basel, Switzerland), and aflibercept (Regeneron Pharmaceuticals Inc) for ROP treatment has been reported in recent years and shown to be efficacious Journal of Ophthalmology
E efficacious of anti-VEGF agents have been certified in several studies and the short-term safety was described, while the peripheral vascular abnormalities of ROP treated with bevacizumab and ranibizumab had been reported in recent years [14,15,16,17]. e most common vascular abnormalities include incomplete vascularization [14, 15], vascular leakage [16, 17], vascular dilation, vascular blunting [16], and capillary dropout [16]

Summary

Clinical Study

Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept versus Ranibizumab for Retinopathy of Prematurity. To evaluate angiographic findings of peripheral retina vasculature in retinopathy of prematurity (ROP) neonates who received intravitreal conbercept (IVC) or ranibizumab (IVR). Outcome measures included peripheral avascular zone, vascular leakage, vascular blunting, vascular loops, vascular dilatation, arteriovenous shunt, and capillary dropout. For the IVC group, FA performed at 71.29–115.43 weeks PMA showed 96.55% of eyes had avascular zone; vascular leakage was found in 24.14% eyes; vascular blunting, vascular dilation, vascular loops, arteriovenous shunt, and capillary dropout were found in 96.55%, 72.41%, 79.31%, 48.28%, and 68.97% eyes, respectively. For the IVR group, FA performed at 65.57–133.71 weeks PMA showed 92.0% of eyes had avascular zone; vascular leakage was found in 40.0% eyes; vascular blunting, dilatation, loops, arteriovenous shunt, and capillary dropout were found in 100%, 60.0%, 64.0%, 36.0%, and 68.0% eyes, respectively. FA studies should be considered to assess the status of the peripheral retinal vasculature to determine therapeutic outcomes and potential functional outcomes

Introduction

Results

Intravitreal ranibizumab

OD OS